The new double-headed antibody targets both CD3 and BCMA, a target that already features in approved therapies for myeloma, including GlaxoSmithKline's first-to-market antibody-drug conjugate (ADC ...

Sales have been modest to date – just £36 million in the third quarter – despite it being the first drug targeting BCMA to reach the market. Now, its hopes lie with two other clinical trials ...

Introduction: Idecabtagene vicleucel (Ide-Cel) and ciltacabtagene autoleucel (Cilta-cel) are novel CAR-T therapies targeting B-cell maturation antigen (BCMA) and approved for relapsed and refractory ...